Because NFYA is a key regulator of HSPA5 transcription [62] and downregulated HSPA5 has been shown in SCA17 lymphoblasts [9], treatments through enhancing NFYA expression may be beneficial to SCA17. The gene discussed is HSPA5; the disease is spinocerebellar ataxia type 17.